Autoimmunity-driven enzymatic remodeling of the dermalepidermal junction in bullous pemphigoid and dermatitis herpetiformis

Autoimmunity

Volumn 45, Issue 1, 2012, Pages 71-80

  Gornowicz Porowska, Justyna ^a   Bowszyc Dmochowska, Monika ^a   Dmochowski, Marian ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Fc receptors; Granulocytes' activation; Proteolytic enzymes; Subepidermal bullous diseases

Indexed keywords

AUTOANTIBODY; COLLAGENASE; EOSINOPHIL CATIONIC PROTEIN; FC RECEPTOR; GELATINASE B; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; INTERLEUKIN 8; LEUKOCYTE ELASTASE; MAJOR BASIC PROTEIN; MYELOPEROXIDASE; PROTEINASE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNITY; BASEMENT MEMBRANE; BLISTER; BULLOUS PEMPHIGOID; DEGRANULATION; DERMATITIS HERPETIFORMIS; DERMOEPIDERMAL JUNCTION; ENZYME MODIFICATION; ENZYME SUBSTRATE; GENOTYPE; HEMATOPOIETIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; MAST CELL; MORPHOLOGY; PATHOGENESIS; PHAGOCYTOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DERMATITIS HERPETIFORMIS; DERMIS; EPIDERMIS; HUMANS; PEMPHIGOID, BULLOUS; PEPTIDE HYDROLASES; PROTEOLYSIS; RECEPTORS, FC; SKIN;

EID: 84856508593     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2011.606448     Document Type: Article

References (70)

1. Mahmood T, Haroon TS. Patterns of direct immunofluorescence in sub-epidermal autoimmune bullous diseases of skin in Lahore, Pakistan. J Pak Assoc Dermatol 2003;13: 67-71. (Pubitemid 37039861)
2. Mulyowa GK, Jaeger G, Sitaru C, Bröcker EB, Zillikens D, Schmidt E. Scarring autoimmune bullous disease in a Ugandan patient with autoantibodies to BP180, BP230, and laminin 5. J Am Acad Dermatol 2006;54(2 Suppl):S43-S46. (Pubitemid 43113087)
3. Lever WF. Pemphigus. Medicine 1953;32:1-123.
4. Liu Z. Immunopathology of bullous pemphigoid, an autoimmune and inflammatory skin blistering disease. Keio J Med 2003;52(2):128-133. (Pubitemid 36834408)
5. Marietta EV, Camilleri MJ, Castro LA, Krause PK, Pittelkow MR, Murray JA. Transglutaminase autoantibodies in dermatitis herpetiformis and celiac sprue. J Invest Dermatol 2007; 128:332-335.
6. Sárdy M, Kárpáti S, Merkl B, Paulsson M, Smyth N. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002;195:747-757. (Pubitemid 34259719)
7. Liu Z, Giudice GJ, Zhou X, Swartz SJ, Troy JL, Fairley JA, Till GO, Diaz LA. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997;100:1256-1263. (Pubitemid 27386312)
8. Nishie W, Sawamura D, Natsuga K, Shinkuma S, Goto M, Shibaki A, Ujiie H, Olasz E, Yancey KB, Shimizu H. A novel humanized neonatal autoimmune blistering skin disease model induced by maternally transferred antibodies. J Immunol 2009;183:4088-4093.
9. MacDonald T, Pender SLF. Proteolytic enzymes in inflammatory bowel disease. Inflamm Bowel Dis 1998;4:157-164. (Pubitemid 128699847)
10. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992;10:145-155.
11. Shimanovich I, Mihai S, Oostingh GJ, Ilenchuk TT, Bröcker EB, Opdenakker G, Zillikens DZ, Sitaru C. Granulocytederived elastase and GB are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 2004;204:519-527. (Pubitemid 39585950)
12. Liu Z, Shipley JM, Vu TH, Zhou X, Diaz LA, Werb Z, Senior RM. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 1998;188:475-482. (Pubitemid 28369137)
13. Briggaman RA, Schechter NM, Fraki J, Lazarus GS. Degradation of the epidermal-dermal junction by proteolytic enzymes from human skin and human poly morphonuclear leukocytes. J Exp Med 1984;160:1027-1042. (Pubitemid 14020965)
14. Fröhlich E. Proteases in cutaneous malignant melanoma: Relevance as biomarker and therapeutic target. Cell Mol Life Sci 2010;67:3947-3960.
15. Zhao M, Trimbeger ME, Li N, Diaz LA, Shapiro SD, Liu Z. Role of FcRs in animal model of autoimmune bullous pemphigoid. J Immunol 2006;177:3398-3405. (Pubitemid 44277860)
16. Korkmaz B, Moreau T, Gauthier F. Neutrophil elastase, proteinase 3 and cathepsin G: Physicochemical properties, activity and physiopathological functions. Biochimie 2008;90: 227-242. (Pubitemid 351187763)
17. Neves JS, Perez SAC, Spencer LA, Melo RCN, Reynolds L, Ghiran I, Mahmudi-Azer S, Odemuyiwa SO, Dvorak AM, Moqbel R, Weller PF. Eosinophil granules function extracellularly as receptor-mediated secretory organelles. Proc Nat Acad Sci 2008;105:18478-18483.
18. Kaminska R, Naukkarinen A, Glinski W, Horsmanheimo M, Harvima IT. Mast cells in developing subepidermal bullous diseases: Emphasis on tryptase, chymase and protease inhibitors. Acta Derm Venereol 1999;79:351-355. (Pubitemid 29414966)
19. Brown EE, Edberg JC, Kimberly RP. Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity 2007;40(8):567-581. (Pubitemid 350302183)
20. Takai T. Fc receptors: Their diverse functions in immunity and immune disorders. Springer Semin Immunopathol 2006;28: 303-304. (Pubitemid 44900569)
21. Vidarsson D, Stemerding AM, Stapleton MN, Spliethoff SE, Janssen H, Rebers FE, de Haas M, van de Winkel JG. FcRn: An IgG receptor on phagocytes with a novel role in phagocytosis. Blood 2006;108:3573-3579.
22. Fossati G, Bucknall RC, Edwards SW. Fcgamma receptors in autoimmune diseases. Eur J Clin Invest 2001;31(9):821-831.
23. Nimmerjahn F, Ravetch JV. Fcg receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
24. Kono H, Kyogoku C, Suzuki T, Tsuchyia N, Honda H, Yamamoto K, Tokunaga K, Honda ZI. FcgRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet 2005;14:2881-2892. (Pubitemid 41418793)
25. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP. A novel polymorphism of FcgrIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-1070. (Pubitemid 27386289)
26. Thabet MM, Huizinga TW,Marques RB, Stoeken-Rijsbergen G, Bakker AM, Kurreeman FA, White SJ, Toes RE. van der Helm-van Mil AH. Contribution of FcgRIIIA gene 158V/F polymorphism and copy number variation to the risk of ACPApositive rheumatoid arthritis. Ann Rheum Dis 2009;68: 1775-1780.
27. Guilabert A, Lozano F, Iranzo P, Julià M, Suárez- Casasús B, Moreno N, Herrero-Gonzalez J, Mascaró JM. The role of Fc gamma receptors polymorphisms in bullous pemphigoid. J Am Acad Dermatol 2010;63(1):161-163.
28. Nestor MS, Cochran AJ, Ahmed AR. Mononuclear cell infiltrates in bullous disease. J Invest Dermatol 1987;88: 172-175. (Pubitemid 17025298)
29. Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007;33:67-77. (Pubitemid 351514141)
30. Caproni M, Feliciani C, Fuligni A, Salvatore E, Atani L, Bianchi B, Pour SM, Proietto G, Toto P, Coscione G, Amerio P, Fabbri P. Th2-like cytokine activity in dermatitis herpetiformis. Br J Dermatol 1998;138:242-247. (Pubitemid 28114125)
31. Niimi Y, Pawankar R, Kawana S. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol 2006;139:104-113. (Pubitemid 43177321)
32. Wiedow O, Meyer-Hoffert U. Neutrophil serine proteases: Potential key regulators of cell signalling during inflammation. J Intern Med 2005;257:319-328. (Pubitemid 40461184)
33. Bank U, Ansorge S. More than destructive: Neutrophilderived serine proteases in cytokine bioactivity control. J Leukoc Biol 2001;69:197-206. (Pubitemid 32163431)
34. Mariotti A, Kedeshian PA, Dans M, Curotola AM, Gagnoux-Palacios L, Giancotti FG. EGFR signaling through Fyn kinase disrupts the function of integrin a6b4 at hemidesmosomes: Role in epithelial cell migration and carcinoma invasion. J Cell Biol 2001;155:447-458.
35. Schmidt E, Reimer S, Kruse N, Jainta S, Bröcker EB, Marinkovich MP, Giudice GJ, Zillikens D. Autoantibodies to BP180 associated to bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol 2000;115:842-848.
36. Hendrix JD, Mangnum KL, Zone JJ, Gammon R. Cutaneous IgA deposits in bullous diseases function as ligands to mediate adherence of activated neutrophils. J Invest Dermatol 1990; 94:667-672. (Pubitemid 20141287)
37. Oikarinen AI, Zone JJ, Ahmed AR, Kiistala U, Uitto J. Demonstration of collagenase and elastase activities in the blister fluids from bullous skin diseases. Comparison between dermatitis herpetiformis and bullous pemphigoid. J Invest Dermatol 1983;81:261-266. (Pubitemid 13045266)
38. Bowszyc-Dmochowska M, Dmochowski M. Immediate hypersensitivity phenomena in bullous pemphigoid: Critical concepts. J Med 2002;33:189-198. (Pubitemid 36896779)
39. Dmochowski M, Gornowicz J, Seraszek A, Kaczmarek E, Bowszyc-Dmochowska M. Neutrophil elastase, eosinophil major basic protein and autoantibodies to BP230 in human bullous pemphigoid lesions JC Bystryn Pemphigus & Pemphigoid Meeting: From the Bench to the Bedside; 2010 Nov 5-6; Bethesda, USA. Program/Abstracts 2010. p 11.
40. Frezzolini A, Teofoli P, Cianchini G, Barduagni S, Ruffelli M, Ferranti G, Puddu P, De Pita O. Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid. Eur J Dermatol 2002;12(1):27-31. (Pubitemid 34131135)
41. Chen R, Ning G, Zhao ML, Fleming MG, Diaz LA, Werb Z, Liu Z. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 2001;108(8): 1151-1158. (Pubitemid 32995373)
42. Kasahara-Imamura M, Hosokawa H, Maekawa N, Horio T. Activation of Fc epsilon RI-positive eosinophils in bullous pemphigoid. Int J Mol Med 2001;7(3):249-253.
43. Cugno M, Tedeschi A, Asero R, Meroni PL, Marzano AV. Skin autoimmunity and blood coagulation. Autoimmunity 2010; 43(2):189-194.
44. Verraes S, Hornebeck W, Polette M, Borradori L, Bernard P. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 2001;117:1091-1096. (Pubitemid 34205902)
45. Zebrowska A, Narbutt J, Sysa-Jedrzejowska A, Kobos J, Waszczykowska E. The imbalance between metalloproteinases and their tissue inhibitors is involved in the pathogenesis of dermatitis herpetiformis. Mediators Inflamm 2005;6: 373-379. (Pubitemid 41803406)
46. Bowszyc-Dmochowska M, Seraszek A, Kaczmarek E, Gornowicz J, Dmochowski M. Low strength of correlation between the intensity of neutrophil elastase expression in lesional skin and the level of serum IgA antibodies to epidermal transglutaminase in dermatitis herpetiformis. Open Autoimmun J 2009;1:1-4.
47. Reunala T. Dermatitis herpetiformis. Clin Dermatol 2001;19: 728-736. (Pubitemid 33035022)
48. Alexander JO. Is eosinophilia of diagnostic importance in dermatitis herpetiformis? Br J Dermatol 1961;73:267-272.
49. Caproni M, Cardinali C, D'Agata A, Selvaggi W, Fabbri P. Serum eosinophil cationic protein, myeloperoxidase, tryptase, eotaxin and Th2-like cytokines in dermatitis herpetiformis. Int Arch Allergy Immunol 2002;128:67-72. (Pubitemid 34621668)
50. Morton HC, Brandtzaeg P. CD89: The human myeloid IgA Fc receptor. Arch Immunol Ther Exp 2001;49:217-229. (Pubitemid 33613992)
51. Gornowicz J, Bowszyc-Dmochowska M, Dmochowski M. Eosinophil-derived neurotoxin (EDN) in relation to IgA autoantibodies to epidermal transglutaminase in dermatitis herpetiformis. Clin Dermatol 2009;11:13-15.
52. Dmochowski M, Gornowicz J, Seraszek A, Kaczmarek E, Bowszyc-Dmochowska M. Cutaneous expression of neutrophil elastase in relation to IgA autoantibodis to nonapeptides of gliadin and tissue transglutaminase in dermatitis herpetiformis. J Invest Dermatol 2011;131(1 Suppl):S2.
53. Wolnik-Trzeciak G, Bowszyc-Dmochowska M, Górna A, Nieruchalska E, Kaczmarek E, Dmochowski M. Eosinophil major basic protein (MBP) in relation to IgA antibodies to epidermal transglutaminase in dermatitis herpetiformis. Clin Dermatol 2005;7:67-71. (Pubitemid 40780403)
54. Salmela MT, Pender SLF, Reunala T, MacDonald T, Saarialho-Kere U. Parallel expression of macrophage metalloelastase (MMP-12) in duodenal and skin lesions of patients with dermatitis herpetiformis. Gut 2001;48:496-502. (Pubitemid 32234793)
55. Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ, Fairley JA, Diaz LA. Neutrophil elastase plays a critical role in experimental bullous pemphigoid. J Clin Invest 2000; 105:113-123. (Pubitemid 30036393)
56. Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, Senior RM,Werb Z. The serpin a1-proteinase inhibitor is a critical substrate for gelatinase B/MMP9 in vivo. Cell 2000; 102:647-655.
57. Pehamberger H, Gschnait F, Konrad K, Holubar K. Bullous pemphigoid, herpes gestationis and linear dermatitis herpetiformis: Circulating anti-basement membrane zone antibodies; in vitro studies. J Invest Dermatol 1980;74:105-108. (Pubitemid 10165169)
58. Yamamoto K, Inoue N, Masada R, Fujimori A, Saito T, Imajoh-Ohmi S, Shinkai H, Sakiyama H. Cloning of hamster type XVII collagen cDNA, and pathogenesis of anti-type XVII collagen antibody and complement in hamster bullous pemphigoid. J Invest Dermatol 2002;118:485-492. (Pubitemid 34227166)
59. Hartenstein B, Dittrich BT, Stickens D, Heyer B, Vu TH, Teurich S, Schropp-Kistner M, Werb Z, Angel P. Epidermal development and wound healing in matrix metalloproteinase 13-deficient mice. J Invest Dermatol 2006;126:486-496. (Pubitemid 43323187)
60. Zone JJ, Egan CA, Taylor TB, Meyer LJ. IgA autoimmune disorders: Development of a passive transfer mouse model. J Investig Dermatol Symp Proc 2004;9:47-51. (Pubitemid 38096198)
61. Zone JJ, Schmidt L, Sotiriou M, TaylorT, Hull CM,Meyer LJ. Deposition of granular immunoglobulin in dermal papillae of human skin by passive transfer of anti-epidermal transglutaminase antibody to SCID mice bearing normal human skin. J Invest Dermatol 2009;129:S135.
62. Zone JJ, Schmidt L, Taylor T, Hull CM, Sotiriou M, Jaskowski TD, Hill HR, Meyer LJ. Dermatitis herpetiformis sera or goat anti-transglutaminase-3 transferred to human skin-grafted mice mimics dermatitis herpetiformis immunopathology. J Immunol 2011;186:4474-4480.
63. Nimmerjahn F. Activating and inhibitory FcgammaRs in autoimmune disorders. Springer Semin Immunopathol 2006; 28:305-319. (Pubitemid 44900570)
64. Yu X, Holdorf K, Kasper B, Zillikens D, Ludwig RJ, Peterson F. Fc gammaRIIA and FcgammaRIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous pemphigoid. J Invest Dermatol 2010;130: 2841-2844.
65. Weisenseel P, Martin S, Partscht K, Messer G, Prinz JC. Relevance of the low-affinity type of the Fcgamma-receptor-IIIA-polymorphism in bullous pemphigoid. Arch Dermatol Res 2007;299:163-164. (Pubitemid 46835384)
66. Trevani AS, Andonegui A, Isturiz MA, Schatner M, Serebrinsky G, Geffner JR. Effect of proteolytic enzymes on neutrophil FcgammaRII activity. Immunology 1994;82: 632-637. (Pubitemid 24263392)
67. Fairley JA, Burnett CT, Fu CL, Larson DL, Fleming MG, Giudice GJ. A pathogenic role for IgE in autoimmunity: Bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007;127:2605-2611. (Pubitemid 47585071)
68. Gomes M, Herr AB. IgA and IgA-specific receptors in human disease: Structural and functional insights into pathogenesis and therapeutic potential. Springer Semin Immunopathol 2006;28:383-395. (Pubitemid 44900577)
69. Wines BD, Hogarth PM. IgA receptors in health and disease. Tissue Antigens 2006;6:103-114. (Pubitemid 44392318)
70. Grando SA,GlukhenkyBT,DrannikGN,Kostromin AP, Boiko YYA, Senyuk OF. Autoreactive cytotoxic T lymphocytes in pemphigus and pemphigoid. Autoimmunity 1989;3:247-260. (Pubitemid 19205875)